These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 38353498)

  • 1. Neoadjuvant chemo- or chemo-radiation-therapy of pancreatic ductal adenocarcinoma differentially shift ECM composition, complement activation, energy metabolism and ribosomal proteins of the residual tumor mass.
    Stillger MN; Kurowski K; Bronsert P; Brombacher E; Kreutz C; Werner M; Tang L; Timme-Bronsert S; Schilling O
    Int J Cancer; 2024 Jun; 154(12):2162-2175. PubMed ID: 38353498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Data independent acquisition of plasma biomarkers of response to neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma.
    O'Rourke MB; Sahni S; Samra J; Mittal A; Molloy MP
    J Proteomics; 2021 Jan; 231():103998. PubMed ID: 33027703
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted and explorative profiling of kallikrein proteases and global proteome biology of pancreatic ductal adenocarcinoma, chronic pancreatitis, and normal pancreas highlights disease-specific proteome remodelling.
    Werner J; Bernhard P; Cosenza-Contreras M; Pinter N; Fahrner M; Pallavi P; Eberhard J; Bronsert P; Rückert F; Schilling O
    Neoplasia; 2023 Feb; 36():100871. PubMed ID: 36610378
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The differential effect of neoadjuvant chemotherapy and chemoradiation on nodal downstaging in pancreatic adenocarcinoma.
    Altimari M; Wells A; Abad J; Chawla A
    Pancreatology; 2023 Nov; 23(7):805-810. PubMed ID: 37599170
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of neoadjuvant therapy on the histopathological features of pancreatic ductal adenocarcinoma - A systematic review and meta-analysis.
    Schorn S; Demir IE; Reyes CM; Saricaoglu C; Samm N; Schirren R; Tieftrunk E; Hartmann D; Friess H; Ceyhan GO
    Cancer Treat Rev; 2017 Apr; 55():96-106. PubMed ID: 28342938
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Temporal Assessment of Prognostic Factors in Patients With Pancreatic Ductal Adenocarcinoma Undergoing Neoadjuvant Treatment and Resection.
    Ren W; Xourafas D; Ashley SW; Clancy TE
    J Surg Res; 2021 Jan; 257():605-615. PubMed ID: 32947122
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Enhanced antitumour immunity following neoadjuvant chemoradiotherapy mediates a favourable prognosis in women with resected pancreatic cancer.
    van Eijck CWF; Mustafa DAM; Vadgama D; de Miranda NFCC; Groot Koerkamp B; van Tienhoven G; van der Burg SH; Malats N; van Eijck CHJ;
    Gut; 2024 Jan; 73(2):311-324. PubMed ID: 37709493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Area of residual tumor (ART) can predict prognosis after post neoadjuvant therapy resection for pancreatic ductal adenocarcinoma.
    Okubo S; Kojima M; Matsuda Y; Hioki M; Shimizu Y; Toyama H; Morinaga S; Gotohda N; Uesaka K; Ishii G; Mino-Kenudson M; Takahashi S
    Sci Rep; 2019 Nov; 9(1):17145. PubMed ID: 31748528
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Histologic grading of the extent of residual carcinoma following neoadjuvant chemoradiation in pancreatic ductal adenocarcinoma: a predictor for patient outcome.
    Chatterjee D; Katz MH; Rashid A; Varadhachary GR; Wolff RA; Wang H; Lee JE; Pisters PW; Vauthey JN; Crane C; Gomez HF; Abbruzzese JL; Fleming JB; Wang H
    Cancer; 2012 Jun; 118(12):3182-90. PubMed ID: 22028089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor-insular Complex in Neoadjuvant Treated Pancreatic Ductal Adenocarcinoma Is Associated With Higher Residual Tumor.
    González IA; Kang LI; Williams GA; Liu J; DeNardo DG; Hawkins WG; Chatterjee D
    Am J Surg Pathol; 2020 Jun; 44(6):817-825. PubMed ID: 32091434
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular targets for diagnostic and intraoperative imaging of pancreatic ductal adenocarcinoma after neoadjuvant FOLFIRINOX treatment.
    Vuijk FA; de Muynck LDAN; Franken LC; Busch OR; Wilmink JW; Besselink MG; Bonsing BA; Bhairosingh SS; Kuppen PJK; Mieog JSD; Sier CFM; Vahrmeijer AL; Verheij J; Fariňa-Sarasqueta A; Swijnenburg RJ
    Sci Rep; 2020 Oct; 10(1):16211. PubMed ID: 33004930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Phase II Clinical Trial of Molecular Profiled Neoadjuvant Therapy for Localized Pancreatic Ductal Adenocarcinoma.
    Tsai S; Christians KK; George B; Ritch PS; Dua K; Khan A; Mackinnon AC; Tolat P; Ahmad SA; Hall WA; Erickson BA; Evans DB
    Ann Surg; 2018 Oct; 268(4):610-619. PubMed ID: 30080723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pancreatic intraepithelial neoplasia and histological changes in non-neoplastic pancreas associated with neoadjuvant therapy in patients with pancreatic ductal adenocarcinoma.
    Chatterjee D; Katz MH; Rashid A; Estrella JS; Wang H; Varadhachary GR; Wolff RA; Lee JE; Pisters PW; Abbruzzese JL; Fleming JB; Wang H
    Histopathology; 2013 Dec; 63(6):841-51. PubMed ID: 24111684
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Proteogenomic insights into the biology and treatment of pancreatic ductal adenocarcinoma.
    Tong Y; Sun M; Chen L; Wang Y; Li Y; Li L; Zhang X; Cai Y; Qie J; Pang Y; Xu Z; Zhao J; Zhang X; Liu Y; Tian S; Qin Z; Feng J; Zhang F; Zhu J; Xu Y; Lou W; Ji Y; Zhao J; He F; Hou Y; Ding C
    J Hematol Oncol; 2022 Nov; 15(1):168. PubMed ID: 36434634
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
    Law HC; Lagundžin D; Clement EJ; Qiao F; Wagner ZS; Krieger KL; Costanzo-Garvey D; Caffrey TC; Grem JL; DiMaio DJ; Grandgenett PM; Cook LM; Fisher KW; Yu F; Hollingsworth MA; Woods NT
    Clin Cancer Res; 2020 Mar; 26(5):1065-1076. PubMed ID: 31848187
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
    Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
    Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathology of Treated Pancreatic Ductal Adenocarcinoma and Its Clinical Implications.
    Nagaria TS; Wang H; Chatterjee D; Wang H
    Arch Pathol Lab Med; 2020 Jul; 144(7):838-845. PubMed ID: 32023088
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Survival benefit of neoadjuvant therapy in patients with non-metastatic pancreatic ductal adenocarcinoma: A propensity matching and intention-to-treat analysis.
    Sugimoto M; Takahashi N; Farnell MB; Smyrk TC; Truty MJ; Nagorney DM; Smoot RL; Chari ST; Carter RE; Kendrick ML
    J Surg Oncol; 2019 Nov; 120(6):976-984. PubMed ID: 31452208
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on the management of pancreatic cancer: surgery is not enough.
    Ansari D; Gustafsson A; Andersson R
    World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proteomic identification of potential prognostic biomarkers in resectable pancreatic ductal adenocarcinoma.
    Iuga C; Seicean A; Iancu C; Buiga R; Sappa PK; Völker U; Hammer E
    Proteomics; 2014 Apr; 14(7-8):945-55. PubMed ID: 24459066
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.